title: [Two cases of successful sorafenib retreatment with the addition of steroid therapy following sorafenib-induced erythema multiforme in two patients with hepatocellular carcinoma].
abstract: Erythema multiforme (EM) is a known side effect of sorafenib therapy in cancer patients; at onset, the causative medication should be permanently discontinued. Here we report two cases of hepatocellular carcinoma (HCC) that developed sorafenib-induced EM. In both cases, retreatment with sorafenib combined with steroid therapy achieved effective tumor control without EM recurrence. The first patient was a 72-year-old woman who showed a dramatic response to sorafenib retreatment, with complete remission after 8 months of therapy. There was no rash recurrence after the steroid dose was gradually tapered and stopped. The second patient was a 69-year-old man who responded to sorafenib and exhibited stable disease, with no recurrence of the rash after the steroid dose was tapered. However, mild hand-foot syndrome persisted throughout sorafenib therapy. Although sorafenib should be discontinued if EM occurs, if there is no suitable alternative treatment, retreatment may be considered with steroid cover in patients with unresectable HCC.
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Shiga University of Medical Science.
authors.forename: Makoto
authors.initials: M
authors.lastname: Shioya
authors.forename: Takashi
authors.initials: T
authors.lastname: Nishimura
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nishida
authors.forename: Osamu
authors.initials: O
authors.lastname: Inatomi
authors.forename: Shigeki
authors.initials: S
authors.lastname: Bamba
authors.forename: Masaya
authors.initials: M
authors.lastname: Sasaki
authors.forename: Akira
authors.initials: A
authors.lastname: Andoh
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Fujiyama
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000188:drug therapy*; D004892:Erythema Multiforme / Q000139:chemically induced* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy*; D008297:Male; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D011239:Prednisolone / Q000008:administration & dosage*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D011239:Prednisolone; D000077157:Sorafenib